Results 261 to 270 of about 1,252,407 (298)
Some of the next articles are maybe not open access.
Immune Checkpoint Inhibitor Toxicity
Current Oncology Reports, 2018Immune checkpoint inhibitors have revolutionised the treatment of multiple malignancies and have a growing list of indications. As our familiarity with these agents grows, so does our understanding of their unique spectrum of toxicities. Here, we will review the literature regarding the toxicities of checkpoint inhibitors and address challenges ...
David J, Palmieri, Matteo S, Carlino
openaire +2 more sources
Radiotherapy, immunity, and immune checkpoint inhibitors
The Lancet OncologyRadiotherapy exerts immunostimulatory and immunosuppressive effects, both locally, within the irradiated tumour microenvironment, and systemically, outside the radiation field. Inspired by preclinical data that showed synergy between radiotherapy and immune checkpoint inhibitors, multiple clinical trials were initiated with the hypothesis that combined
Connor, Lynch +2 more
openaire +2 more sources
Lipid Metabolism and Immune Checkpoints
2021Immune checkpoints are essential for the regulation of immune cell functions. Although the abrogation of immunosurveillance of tumor cells is known, the regulators of immune checkpoints are not clear. Lipid metabolism is one of the important metabolic activities in organisms.
Qianjin, Liao +3 more
openaire +2 more sources
Immune Checkpoints in Viral Latency
Annual Review of Microbiology, 2001▪ Abstract The dynamics of the relationship between the immune system and latent viruses are highly complex. Latent viruses not only avoid elimination by the host's primary immune response, they also remain with the host for life in the presence of strong acquired immunity, often exhibiting periodic reactivation and recurrence from the latent state ...
S, Redpath +3 more
openaire +2 more sources
Cardiotoxicity of Immune Checkpoint Inhibitors
Current Treatment Options in Cardiovascular Medicine, 2019Immunotherapies, particularly immune checkpoint inhibitors (ICI), are revolutionary cancer therapies being increasingly applied to a broader range of cancers. Our understanding of the mechanism, epidemiology, diagnosis, and treatment of cardiotoxicity related to immunotherapies remains limited.
Lili, Zhang +8 more
openaire +2 more sources
Immune checkpoints in the tumor microenvironment
Seminars in Cancer Biology, 2020Interactions between immune checkpoints (ICs) and their ligands negatively regulate T cell activation pathways involved in physiological immune responses against specific antigens. ICs and their ligands are frequently upregulated in the tumor microenvironment (TME) of various malignancies, and they represent significant barriers for induction of ...
Salman M, Toor +3 more
openaire +2 more sources
Melanoma and Immune Checkpoint Inhibitors
Current Oncology Reports, 2018Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8 months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients.
Masutaka, Furue +5 more
openaire +2 more sources
The future of immune checkpoint therapy
Science, 2015Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for ...
Padmanee, Sharma, James P, Allison
openaire +2 more sources
Immune Checkpoint Therapy in Melanoma
The Cancer Journal, 2016Checkpoint-blocking antibodies have transformed cancer therapy, and the treatment of patients with metastatic melanoma has led the revolution. Herein, we review the current clinical data supporting the use of checkpoint-blocking antibodies in the treatment of melanoma and highlight outstanding clinical questions and unmet clinical needs.
openaire +2 more sources
Combined Immune Checkpoint Blockade
Seminars in Oncology, 2015There are very few tumor types for which chemotherapy regimens are regularly curative; notable exceptions include testicular cancer and Hodgkin's lymphoma. In both cases combination chemotherapy approaches are required. Thus, it would seem only logical that combination immunotherapy approaches will be required to induce long-term remissions in the ...
openaire +2 more sources